After several months, inflammatory disease medication Dupixent has finally reclaimed its spot atop the rankings for over-the-counter (OTC) and Rx brand marketing on TV. The Regeneron and Sanofi brand, ...
Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...
In Q3, the top 10 TV ad spenders poured a combined $544.8 million into airing their commercials, according to data shared ...
Hosted on MSN
Regeneron’s Blockbuster Dupixent Faces a New Rival
With $17 billion in annual sales, Dupixent is a franchise drug for its 50/50 owners Sanofi and Regeneron Pharmaceuticals. So rivals have lined up to challenge the antibody treatment against autoimmune ...
Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with ...
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback